虾青素对肝纤维化大鼠的保护作用及机制研究*

doi:10.3969/j.issn.1672-5069.2018.06.005

摘要/Abstract

摘要： 目的研究虾青素抑制肝纤维化作用是否与影响TGF-β1/Smad/ERK通路有关。方法将50只大鼠随机分为正常组、模型组、秋水仙碱组（0.1 mg·kg^-1）、虾青素Ⅰ组（2 mg·kg^-1）和虾青素Ⅱ组（4 mg·kg^-1）,每组10只。采用皮下注射CCl₄法制备肝纤维化大鼠模型。在造模成功后,给予正常组和模型组动物生理盐水、而在药物干预组则分别给予秋水仙碱和虾青素灌胃,连续给药6 w。分别采用免疫组化法和Western blot法检测肝组织Ⅰ型胶原、Smad2、转化生长因子-β1（TGF-β1）和p-ERK蛋白表达,采用RT-PCR法检测肝组织CollagenⅠ、Smad2、TGF-β1 和p-ERK mRNA水平。结果正常组、虾青素Ⅰ组和虾青素Ⅱ组肝组织Ⅰ型胶原蛋白分别为（0.4±0.1）、（1.4±0.3）和（1.2±0.3）,均显著低于模型组【（1.7±0.4）,P<0.05】,Smad2分别为（0.5±0.1）、（1.3±0.4）和（0.8±0.4）,显著低于模型组【（1.6±0.3）,P<0.05】,TGF-β1蛋白分别为（0.5±0.1）、（1.4±0.4）和（1.2±0.3）,显著低于模型组【（1.7±0.4）,P<0.05】,p-ERK蛋白分别为（0.4±0.1）、（1.3±0.4）和（0.9±0.3）,显著低于模型组【（1.6±0.5）,P<0.05】;正常组、虾青素Ⅰ组和虾青素Ⅱ肝组织Ⅰ型胶原 mRNA水平分别为（1.0±0.1）、（2.0±0.4）和（1.8±0.5）,均显著低于模型组【（2.4±0.4）,P<0.05】,Smad2 mRNA水平分别为（1.0±0.1）、（2.0±0.5）和（1.8±0.4）,显著低于模型组【（2.5±0.6）,P<0.05】,TGF-β1 mRNA水平分别为（1.0±0.1）、（2.1±0.4）和（1.6±0.3）,均显著低于模型组【（2.5±0.5）,P<0.05】,p-ERK mRNA水平分别为（1.1±0.1）、（2.1±0.4）和（1.8±0.3）,均明显低于模型组【（2.6±0.5）,P<0.05】。结论虾青素可抑制肝纤维化进展,其机制可能与调控TGF-β1/Smad/ERK通路表达有关。

关键词: 肝纤维化, 虾青素, TGF-β1/Smad/ERK通路, 大鼠

Abstract: Objective To investigate the protective effect of astaxanthin on hepatic fibrosis and the mechanism by which the TGF-β1/Smad/ERK pathway involved. Methods 50 male SD rats were randomly divided into control,model,colchicine （0.1 mg·kg^-1）,astaxanthin group I （2 mg·kg^-1） and astaxanthin groupⅡ（4 mg·kg^-1）-intervened groups with 10 rats in each group. A rat model of hepatic fibrosis was established by subcutaneous injection of carbon tetrachloride. At 10th week of modeling,rats in each group were respectively given intragastric administration of colchicines or astaxanthin except in control and model with normal salt,for 6 weeks. The expression of type I collagen,Smad2,transforming growth factor-β1（TGF-β1） and p-ERK protein in liver tissues was detected by immunohistochemistry and Western blot,and the collagen I,Smad2,TGF- beta 1 and p-ERK mRNA in liver tissues was detected by RT-PCR. Results The collagen I protein in the liver tissues of control,astaxanthin group I and astaxanthin group II were （0.4±0.1）,（1.4±0.3） and （1.2±0.3）,respectively,significantly lower than [（1.7±0.4）,P<0.05] in the model,Smad2 protein was（0.5±0.1）,（1.3±0.4） and（0.8±0.4）,much lower than [（1.6±0.3）,P<0.05] in the model,TGF-β1 protein was（0.5±0.1）,（1.4±0.4） and （1.4±0.4）,significantly lower than[（1.7±0.4）,P<0.05] in the model,and the p-ERK protein was（0.4 ± 0.1）,（1.3±0.4） and（0.9±0.3）,respectively,also significantly lower than[（1.6±0.5）,P<0.05] in the model;the hepatic collagen I mRNA levels in the control,astaxanthin group I and astaxanthin group II were （1.0±0.1）,（2.0±0.4） and （1.8±0.5）,significantly lower than[（2.4±0.4）,P<0.05] in the model,the Smad2 mRNA were（1.0 ± 0.1）,（2.0±0.5） and （1.8±0.4）,significantly lower than[（2.5±0.6）,P<0.05] in the model,the TGF-β1 mRNA were（1.0±0.1）,（2.1±0.4） and （1.6±0.3）,much lower than [（2.5±0.5）,P<0.05] in the model,and the p-ERK mRNA levels were （1.1±0.1）,（2.1±0.4） and（1.8±0.3）,respectively,also significantly lower than[（2.6±0.5）,P<0.05] in the model. Conclusion Astaxanthin can inhibit the progression of hepatic fibrosis,which might be related to the down-regulation of TGF-β1/Smad/ERK pathway activation.

Key words: Hepatic fibrosis, Astaxanthin, TGF-β1/Smad/ERK pathway, Rats

刘恩强, 陈果, 廖修用, 许美凤, 魏贵玉, 罗小平. 虾青素对肝纤维化大鼠的保护作用及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 842-846.

Liu Enqiang, Chen Guo, Liao Xiuyong, et al.. Inhibition of TGF-β1/Smad/ERK passway by astaxanthin in rats with CCl₄-induced liver fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 842-846.

参考文献

[1] Jiménez JV,Carrillo-Pérez DL,Rosado-Canto R,et al.Electrolyte and acid-base disturbances in end-stage liver disease:A physiopathological approach. Dig Dis Sci,2017,62(8):1855-1871.
[2] Martin K,Pritchett J,Llewellyn J,et al.PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun,2016,7:12502.
[3] Machicado C,Machicado JD,Maco V,et al.Association of fasciola hepatica infection with liver fibrosis,cirrhosis,and cancer:A systematic review. PLoS Negl Trop Dis,2016,10(9):e0004962.
[4] Walling AM,Ahluwalia SC,Wenger NS,et al.Palliative care quality indicators for patients with end-stage liver disease due to cirrhosis. Dig Dis Sci,2017,62(1):84-92.
[5] Xu F,Liu C,Zhou D,et al.TGF-β/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem,2016,64(3):157-167.
[6] Wu K,Ye C,Lin L,et al.Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. Clin Sci(Lond),2016,130(16):1469-1480.
[7] Gao J,Qin XJ,Jiang H,et al.Detecting serum and urine metabolic profile changes of CCl4-liver fibrosis in rats at 12 weeks based on gas chromatography-mass spectrometry. Exp Ther Med,2017,14(2):1496-1504.
[8] Besheer T,Razek AAKA,E Bendary M,et al. Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4 Turk [J] Gastroenterol,2017,28(4):283-288.
[9] Zhang S,Wu Y,Liu Z,et al.Hepatic pathology of biliary atresia:A new comprehensive evaluation method using liver biopsy. Turk J Gastroenterol,2016,27(3):257-263.
[10] Sun J,Zhang H,Li L,et al.MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncol Rep,2017,37(3):1698-1706.
[11] Li X,Jin Q,Yao Q,et al.Quercetin attenuates the activation of hepatic stellate cells and liver fibrosis in mice through modulation of HMGB1-TLR2/4-NF-κB signaling pathways. Toxicol Lett,2016,261:1-12.
[12] Wu K,Ye C,Lin L,et al.Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. Clin Sci (Lond),2016,130(16):1469-1480.
[13] Arteaga M,Shang N,Ding X, et al.Inhibition of SIRT2 suppresses hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol,2016,310(11):G1155-1168.
[14] Ko HS,Park BJ,Choi SK,et al.STAT3 and ERK signaling pathways are implicated in the invasion activity by oncostatin M through induction of matrix metalloproteinases 2 and 9. Yonsei Med J,2016,57(3):761-768.
[15] 汪美凤,平键,成扬. 肝星状细胞主要信号转导通路与肝纤维化的关系. 实用肝脏病杂志,2010,13(6):466-469.
[16] 蔡乐斌,陶娜. 聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者疗效及对血清细胞因子和肝纤维化指标的影响. 实用肝脏病杂志,2016,19(5):532-535.
[17] Chen N,Geng Q,Zheng J,et al.Suppression of the TGF-β/Smad signaling pathway and inhibition of hepatic stellate cell proliferation play a role in the hepatoprotective effects of curcumin against alcohol-induced hepatic fibrosis. Int J Mol Med,2014,34(4):1110-1116.
[18] Bian Z,Miao Q,Zhong W,et al.Treatment of cholestatic fibrosis by altering gene expression of Cthrc1:Implications for autoimmune and non-autoimmune liver disease. J Autoimmun,2015,63:76-87.
[19] Turner AW,Martinuk A,Silva A,et al.Functional analysis of a novel genome-wide association study signal in SMAD3 that confers protection from coronary artery disease. Arterioscler Thromb Vasc Biol,2016,36(5):972-983.